{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:39:55Z","timestamp":1783575595023,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-023-05369-3","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T17:04:22Z","timestamp":1702314262000},"page":"1173-1182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The effect of orlistat in the treatment of non-alcoholic fatty liver in adolescents with overweight and obese"],"prefix":"10.1007","volume":"183","author":[{"given":"Arefeh","family":"Zahmatkesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Sohouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Shojaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Rohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"5369_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140908","volume":"10","author":"EL Anderson","year":"2015","unstructured":"Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A (2015) The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 10:e0140908","journal-title":"PLoS ONE"},{"key":"5369_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/ijms17060947","volume":"17","author":"JL Temple","year":"2016","unstructured":"Temple JL, Cordero P, Li J, Nguyen V, Oben JA (2016) A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci 17:947","journal-title":"Int J Mol Sci"},{"key":"5369_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/apt.17096","volume":"56","author":"J Li","year":"2022","unstructured":"Li J, Ha A, Rui F, Zou B, Yang H, Xue Q, Hu X, Xu Y, Henry L, Barakat M (2022) Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000\u20132021. Aliment Pharmacol Ther 56:396\u2013406","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"5369_CR4","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1017\/S1368980010000492","volume":"13","author":"J Ma","year":"2010","unstructured":"Ma J, Wang Z, Song Y, Hu P, Zhang B (2010) BMI percentile curves for Chinese children aged 7\u201318 years, in comparison with the WHO and the US Centers for Disease Control and Prevention references. Public Health Nutr 13(12):1990\u20131996","journal-title":"Public Health Nutr"},{"key":"5369_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.663351","volume":"12","author":"CS Friesen","year":"2021","unstructured":"Friesen CS, Hosey-Cojocari C, Chan SS, Csanaky IL, Wagner JB, Sweeney BR, Friesen A, Fraser JD, Shakhnovich V (2021) Efficacy of weight reduction on pediatric nonalcoholic fatty liver disease: opportunities to improve treatment outcomes through pharmacotherapy. Front Endocrinol (Lausanne) 12:663351","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5369_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2036.2004.02153.x","volume":"20","author":"S Harrison","year":"2004","unstructured":"Harrison S, Fincke C, Helinski D, Torgerson S, Hayashi P (2004) A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20:623\u2013628","journal-title":"Aliment Pharmacol Ther"},{"key":"5369_CR7","doi-asserted-by":"publisher","first-page":"175628481987904","DOI":"10.1177\/1756284819879047","volume":"12","author":"J Ye","year":"2019","unstructured":"Ye J, Wu Y, Li F, Wu T, Shao C, Lin Y, Wang W, Feng S, Zhong B (2019) Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Ther Adv Gastroenterol 12:1756284819879047","journal-title":"Ther Adv Gastroenterol"},{"key":"5369_CR8","doi-asserted-by":"crossref","unstructured":"Ali Khan R, Kapur P, Jain A, Farah F, Bhandari U (2017) Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. Therap Clin Risk Manag 139\u2013149","DOI":"10.2147\/TCRM.S124621"},{"key":"5369_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/hep.22575","volume":"49","author":"SA Harrison","year":"2009","unstructured":"Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:80\u201386","journal-title":"Hepatology"},{"key":"5369_CR10","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1007\/s10620-006-9631-1","volume":"52","author":"O Hussein","year":"2007","unstructured":"Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N (2007) Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 52:2512\u20132519","journal-title":"Dig Dis Sci"},{"key":"5369_CR11","first-page":"189","volume":"12","author":"T Sabuncu","year":"2003","unstructured":"Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB (2003) The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 12:189\u2013192","journal-title":"Rom J Gastroenterol"},{"key":"5369_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17512433.2017.1365599","volume":"10","author":"S Liyanagedera","year":"2017","unstructured":"Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP (2017) The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 10:1225\u20131237","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5369_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/oby.2002.87","volume":"10","author":"JR McDuffie","year":"2002","unstructured":"McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA (2002) Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 10:642\u2013650","journal-title":"Obes Res"},{"key":"5369_CR14","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"J-P Chanoine","year":"2005","unstructured":"Chanoine J-P, Hampl S, Jensen C, Boldrin M, Hauptman J (2005) Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293:2873\u20132883","journal-title":"JAMA"},{"key":"5369_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1517\/14740338.2015.994502","volume":"14","author":"B Halpern","year":"2015","unstructured":"Halpern B, Halpern A (2015) Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf 14:305\u2013315","journal-title":"Expert Opin Drug Saf"},{"key":"5369_CR16","doi-asserted-by":"crossref","unstructured":"Baranowski T, Taveras EM (2018) Childhood obesity prevention: changing the focus. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA, pp 1\u20133","DOI":"10.1089\/chi.2017.0303"},{"key":"5369_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1249\/01.MSS.0000117161.66394.07","volume":"36","author":"PC Hallal","year":"2004","unstructured":"Hallal PC, Victora CG (2004) Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc 36:556","journal-title":"Med Sci Sports Exerc"},{"key":"5369_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499\u2013502","journal-title":"Clin Chem"},{"key":"5369_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hep.22336","volume":"48","author":"V Nobili","year":"2008","unstructured":"Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P (2008) Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48:119\u2013128","journal-title":"Hepatology"},{"key":"5369_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/01.mpg.0000177314.65824.4d","volume":"41","author":"MV Louthan","year":"2005","unstructured":"Louthan MV, Theriot JA, Zimmerman E, Stutts JT, McClain CJ (2005) Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr 41:426\u2013429","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5369_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12581","volume":"15","author":"A Seth","year":"2020","unstructured":"Seth A, Orkin S, Yodoshi T, Liu C, Fei L, Hardy J, Trout AT, Arce Clachar AC, Bramlage K, Xanthakos S (2020) Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease. Pediatr Obes 15:e12581","journal-title":"Pediatr Obes"},{"key":"5369_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11154-009-9111-y","volume":"10","author":"AB Wald","year":"2009","unstructured":"Wald AB, Uli NK (2009) Pharmacotherapy in pediatric obesity: current agents and future directions. Rev Endocr Metab Disord 10:205\u2013214","journal-title":"Rev Endocr Metab Disord"},{"key":"5369_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/jpc.12252","volume":"49","author":"CC Yu","year":"2013","unstructured":"Yu CC, Li AM, Chan KO, Chook P, Kam JT, Au CT, So RC, Sung RY, McManus AM (2013) Orlistat improves endothelial function in obese adolescents: a randomised trial. J Paediatr Child Health 49:969\u2013975","journal-title":"J Paediatr Child Health"},{"key":"5369_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4158\/EP.12.1.18","volume":"12","author":"D Maahs","year":"2006","unstructured":"Maahs D, De Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS (2006) Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 12:18\u201328","journal-title":"Endocr Pract"},{"key":"5369_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/jclinpath-2022-208246","volume":"75","author":"C Wang","year":"2022","unstructured":"Wang C, Pai AK, Putra J (2022) Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. J Clin Pathol 75:443\u2013451","journal-title":"J Clin Pathol"},{"key":"5369_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/vetsci8110274","volume":"8","author":"Z Zakaria","year":"2021","unstructured":"Zakaria Z, Othman ZA, Bagi Suleiman J, Jalil NAC, Ghazali WSW, Mohamed M (2021) Protective and therapeutic effects of orlistat on metabolic syndrome and oxidative stress in high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) in rats: role on Nrf2 activation. Veterinary sciences 8:274","journal-title":"Veterinary sciences"},{"key":"5369_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajg.2020.12.005","volume":"22","author":"VAW Esmail","year":"2021","unstructured":"Esmail VAW, Mohammed MO, Al-Nimer MS (2021) Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab Journal of Gastroenterology 22:1\u20135","journal-title":"Arab Journal of Gastroenterology"},{"key":"5369_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/children4060048","volume":"4","author":"H Bush","year":"2017","unstructured":"Bush H, Golabi P, Younossi ZM (2017) Pediatric non-alcoholic fatty liver disease. Children 4:48","journal-title":"Children"},{"key":"5369_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1272\/jnms.84.125","volume":"84","author":"BAM Al-Tahami","year":"2017","unstructured":"Al-Tahami BAM, Ab AA-SI, Sanip Z, Yusoff Z, Shihabudin TMT, Singh TSP, Rasool AHG (2017) Metabolic and inflammatory changes with orlistat and sibutramine treatment in obese Malaysian subjects. J Nippon Med Sch 84:125\u2013132","journal-title":"J Nippon Med Sch"},{"key":"5369_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1172\/JCI14120","volume":"108","author":"TP Combs","year":"2001","unstructured":"Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Investig 108:1875\u20131881","journal-title":"J Clin Investig"},{"key":"5369_CR31","doi-asserted-by":"crossref","unstructured":"Ke J, An Y, Cao B, Lang J, Wu N, Zhao D (2020) Orlistat-induced gut microbiota modification in obese mice. Evidence-Based Complementary and Alternative Medicine (eCAM)","DOI":"10.1155\/2020\/9818349"},{"key":"5369_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12902-023-01390-7","volume":"23","author":"Z Nikniaz","year":"2023","unstructured":"Nikniaz Z, Nikniaz L, Farhangi MA, Mehralizadeh H, Salekzamani S (2023) Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis. BMC Endocr Disord 23:142","journal-title":"BMC Endocr Disord"},{"key":"5369_CR33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2265.2007.02888.x","volume":"67","author":"M Sahin","year":"2007","unstructured":"Sahin M, Tanaci N, Yucel M, Tutuncu NB, Guvener N (2007) The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients. Clin Endocrinol 67:346\u2013350","journal-title":"Clin Endocrinol"},{"key":"5369_CR34","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1172\/JCI21047","volume":"113","author":"S Nielsen","year":"2004","unstructured":"Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Investig 113:1582\u20131588","journal-title":"J Clin Investig"},{"key":"5369_CR35","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1172\/JCI6572","volume":"104","author":"EJ Parks","year":"1999","unstructured":"Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK (1999) Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Investig 104:1087\u20131096","journal-title":"J Clin Investig"},{"key":"5369_CR36","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s00330-018-5900-6","volume":"29","author":"DW Kim","year":"2019","unstructured":"Kim DW, Park C, Yoon HM, Jung AY, Lee JS, Jung SC, Cho YA (2019) Technical performance of shear wave elastography for measuring liver stiffness in pediatric and adolescent patients: a systematic review and meta-analysis. Eur Radiol 29:2560\u20132572","journal-title":"Eur Radiol"},{"key":"5369_CR37","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1111\/j.2047-6310.2013.00209.x","volume":"9","author":"V Nobili","year":"2014","unstructured":"Nobili V, Alisi A, Grimaldi C, Liccardo D, Francalanci P, Monti L, Castellano A, de Ville de Goyet J (2014) Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes 9:e99\u2013e102","journal-title":"Pediatr Obes"},{"key":"5369_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1210\/er.2008-0009","volume":"29","author":"N Stefan","year":"2008","unstructured":"Stefan N, Kantartzis K, H\u00e4ring H-U (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939\u2013960","journal-title":"Endocr Rev"},{"key":"5369_CR39","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.2337\/db06-S002","volume":"55","author":"K Morino","year":"2006","unstructured":"Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55:S9\u2013S15","journal-title":"Diabetes"},{"key":"5369_CR40","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Investig 116:1793\u20131801","journal-title":"J Clin Investig"},{"key":"5369_CR41","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/hep.29068","volume":"65","author":"I Doycheva","year":"2017","unstructured":"Doycheva I, Watt KD, Alkhouri N (2017) Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology 65:2100\u20132109","journal-title":"Hepatology"},{"key":"5369_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1515\/sjph-2015-0020","volume":"54","author":"P Kotnik","year":"2015","unstructured":"Kotnik P, Posovszky PF, Wabitsch M (2015) Endocrine and metabolic effects of adipose tissue in children and adolescents\/Endokrina in presnovna funkcija ma\u0161\u010dobnega tkiva pri otrocih in mladostnikih. Slovenian Journal of Public Health 54:131\u2013138","journal-title":"Slovenian Journal of Public Health"},{"key":"5369_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1262-3636(07)70161-1","volume":"31","author":"D Kiortsis","year":"2005","unstructured":"Kiortsis D, Filippatos T, Elisaf M (2005) The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 31:15\u201322","journal-title":"Diabetes Metab"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05369-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T14:09:43Z","timestamp":1710857383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05369-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["5369"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05369-3","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the research council and ethics committee Tehran University of Medical Sciences, Tehran, Iran (no: IR.TUMS.CHMC.REC.1401.016). The study has been registered in IRCT (IRCT20220409054467N2, with a registration date of 2022\u201305-13).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}